Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
2022年11月8日 - 9:05PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology
company advancing new treatments for patients suffering from
serious diseases underserved by current therapies, today announced
that management will participate in the Guggenheim 4th Annual
Neuro/Immunology Conference on Tuesday, November 15, 2022.
Guggenheim 4th Annual
Neuro/Immunology Conference
Format: |
Fireside
Chat |
Date: |
November 15, 2022 |
Time: |
1:35 p.m. ET |
Webcast link: |
Registration link |
The live webcast and a replay of the fireside chats can also be
accessed under “Events” in the Investors section of the Viridian
Therapeutics website.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases
underserved by current therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and
incorporates half-life extension technology. VRDN-003 is an
extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003
are designed for administration as convenient, low-volume,
subcutaneous injections. TED is a debilitating autoimmune disease
that causes inflammation and fibrosis within the orbit of the eye
which can cause double vision, pain, and potential blindness.
Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:John JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024